Table 1.
Summary of EBV proteins expressed during latency period.
| EBV latency gene products | Summary of findings | References |
|---|---|---|
| EBERs | High expression in EBV positive gastric carcinoma | (36, 37) |
| upregulates the expression of insulin growth factor-1 | (38) | |
| cooperate with IL-6-STAT3 signaling pathway | (39) | |
| downregulation of miR-200 family | (35) | |
| EBNA-1 | High expression in EBV-positive gastric carcinoma | (40, 41) |
| Assist EBV in binding to host chromosomes | (42) | |
| Protect EBVDNA | (44) | |
| Adjust the miR34a-NOX2-ROS signal. | (43) | |
| Downregulation of miR-200 family | (35) | |
| Change the expression of p53 gene | (21) | |
| LMP-2A | Expression in EBV-positive gastric carcinoma | (36, 37) |
| Downregulation of miR-200 family | (35) | |
| Activates NF-κ B-Survivin pathway | (51, 52) | |
| Regulates the expression of cyclin E and the proportion of S phase cells | (53) | |
| Mediates Notch signal | (54) | |
| Downregulates HLA | (58) | |
| Activates PI3K/AKT pathway | (60) | |
| Upregulates miR155-5p thus inhibiting smad2 and p-smad2. | (55, 56) | |
| Induces STAT3 phosphorylation | (61) | |
| Up-regulate FOXO1 and FOXO3 | (59) | |
| Suppresses COX-2 by reducing TRAF2 | (57) | |
| Activates CpG island methylation of AQP3 promoter | (55) | |
| Downregulates the expression of TET2 | (45) | |
| BARF0 | Downregulation of miR-200 family | (35) |
| Downregulates the expression of TET2 | (45) | |
| BARF1 | Induces NFκB/miR-146a/SMAD4 alterations | (47) |
| Triggers caspase-dependent mitochondrial apoptosis | (46) | |
| Activates NF-κ B-Survivin pathway | (48) | |
| Induces the expression of CyclinD1 protein | (49) | |
| Activates the cell-cycle regulator bcl-2. | (50) |